Retatrutide may become an option in the future if regulators approve it
Heres what you'll learn: Why GLP-1 receptors throughout the mesolimbic system make these medications psychiatric tools, not just metabolic ones Evidence-based patient selection criteria (mechanism over BMI) How to navigate the scope of practice question Clinical decision frameworks for real-world implementation Why force multipliers matter for the approaching workforce crisis FAQs for clinical guidance Read on or listen to the full Psychiatry Tomorrow episode below: The Neurobiological Case for GLP-1s for Mental Health GLP-1 isn't only produced in gut L-cells
Lilly Trial Connect: provides sponsor information for clinical trial searches
Istradefylline: first global approval
Tirzepatide (Zepbound, Mounjaro), a GLP-1 agonist as well as being a GIP further suppressing appetite, was recently compared head-to-head in a NEJM article to semaglutide (Ozempic, Wegovy) which is only a GLP-1 agonist
DIM has shown an ability to metabolize excess estrogen, which can be helpful for people with estrogen dominance or other hormone imbalances making it one of the best vitamins for hormonal acne
